ARTICLE | Company News
Eisai grants CY Biotech Greater China rights to lorcaserin
August 3, 2018 5:45 PM UTC
Eisai Co. Ltd. (Tokyo:4523) granted exclusive rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356) in Greater China, including Hong Kong and Macao.
Under the deal, Eisai will receive a one-time contractual payment and be eligible for regulatory milestones. It will also gain an option to co-promote lorcaserin in China, as well as an option to market lorcaserin in Hong Kong and Macao. It will supply lorcaserin to CY Biotech...